Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Clinical outcomes of cryopreserved graft recipients following allo-HCT

Andriyana K. Bankova, MD, Stanford University School of Medicine, Stanford, CA, discusses the single-center clinical outcomes in recipients of cryopreserved grafts following reduced-intensity conditioning allogeneic hematopoietic cell transplantation (allo-HCT). The findings from this study suggest that the use of cryopreserved allogeneic donor apheresis products results in inferior overall survival and a difference in graft composition between the two approaches. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.